SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Japan Signals Preference for Low Interest Rates as BOJ Policy Debate Intensifies 
Asian Markets Rally as Micron and Qualcomm AI Outlook Lifts Global Tech Stocks 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
BOJ Hawk Signals Faster Interest Rate Hikes Amid Inflation Risks 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Asian Stocks Sink as Apple Price Hikes Spark AI Valuation Fears, South Korea and Japan Lead Selloff 
Australia Jobs Growth Strengthens Rate Hike Outlook 
Wall Street Ends Lower as AI Stocks Drag Markets, Fed Rate Outlook Shifts 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Morgan Stanley Sees Chinese Auto Market Recovery Gaining Momentum in Late Summer 
Iran Attack in Strait of Hormuz Pushes Oil Prices Higher 
Gold Drops Below $4,000 as Strong US Dollar and Fed Rate Hike Expectations Pressure Bullion 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Moderna Inc. enters a historic $1 billion deal with China to research, develop, and produce exclusive mRNA medicines in the country. The agreement, announced amid growing Sino-American tensions, signifies Beijing's increasing openness to foreign pharmaceutical involvement.
The Cambridge, Massachusetts-based pharmaceutical and biotechnology company announced the new deal with Chinese officials on Wednesday, July 5. The agreement is for Moderna to research, develop and produce messenger RNA medicines in the country.
CNBC noted that an agreement was reached despite the growing tensions between China and the United States. Moderna and Beijing signed a memorandum of understanding (MOU) and land collaboration deal to develop drugs that will be made "exclusively for the Chinese people." This means the two sides agreed that the new drug would never be exported and remain in China.
A local media publication reported earlier this week that Moderna is set to invest about $1 billion in the project. It was added that Moderna's chief executive officer, Stephane Bancel, is set to visit Shanghai, possibly to talk more about the deal and for facility inspection.
"These agreements are focused on strengthening health security by targeting unmet needs and contributing to the ecosystem of medical solutions available to patients in China," the company's spokesman stated.
In a separate statement that was sent to Yahoo Finance, Moderna said, "We signed a memorandum of understanding and a related land collaboration agreement to work toward opportunities for Moderna to research, develop and manufacture mRNA medicines in China."
The deal shows that Moderna is trying to take advantage of the success of its COVID-19 vaccine that has been used on people worldwide. The vaccine used a platform called mRNA to push human cells to make an immune response against a virus. At any rate, the agreement was sealed on Wednesday, and this is Moderna's very first deal with the Chinese government.
Photo by: Ian Hutchinson/Unsplash
